SPOTLIGHT: Boehringer launch aided by charity

Boehringer Ingelheim launched its blood thinner Pradaxa last week, getting a media boost from the backing of Lifeblood, a charity that's been lobbying for changes to the National Institute for Clinical Excellence's thrombosis treatment guidelines. Release | Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.